NewGenIvf Group Financials
This page shows NewGenIvf Group (NIVF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
NewGenIvf Group has an operating margin of -21.4%, meaning the company retains $-21 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 0.8% the prior year.
NewGenIvf Group's revenue grew 5.8% year-over-year to $5.4M, a solid pace of expansion. This earns a growth score of 45/100.
NewGenIvf Group's current ratio of 1.17 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.
While NewGenIvf Group generated -$8.3M in operating cash flow, capex of $53K consumed most of it, leaving -$8.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
NewGenIvf Group passes 2 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, NewGenIvf Group generates $15.75 in operating cash flow (-$8.3M OCF vs -$525K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
NewGenIvf Group earns $-1.5 in operating income for every $1 of interest expense (-$1.2M vs $765K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
NewGenIvf Group generated $5.4M in revenue in fiscal year 2024. This represents an increase of 5.8% from the prior year.
NewGenIvf Group's EBITDA was -$1.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1654.2% from the prior year.
NewGenIvf Group generated -$8.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 353.0% from the prior year.
NewGenIvf Group reported -$525K in net income in fiscal year 2024. This represents a decrease of 503.0% from the prior year.
NewGenIvf Group earned $-0.64 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 118.1% from the prior year.
NewGenIvf Group held $458K in cash against $0 in long-term debt as of fiscal year 2024.
NewGenIvf Group had 1M shares outstanding in fiscal year 2024. This represents an increase of 124.4% from the prior year.
NewGenIvf Group's gross margin was 33.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the prior year.
NewGenIvf Group's operating margin was -21.4% in fiscal year 2024, reflecting core business profitability. This is down 22.2 percentage points from the prior year.
NewGenIvf Group's net profit margin was -9.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 12.2 percentage points from the prior year.
NewGenIvf Group invested $53K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 24.1% from the prior year.
NIVF Income Statement
| Metric | Q4'24 | Q4'23 | Q4'22 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
NIVF Balance Sheet
| Metric | Q4'24 | Q4'23 | Q4'22 |
|---|---|---|---|
| Total Assets | $3.6M-20.3% | $4.5M+54.5% | $2.9M |
| Current Assets | $3.2M+29.0% | $2.5M+2.5% | $2.4M |
| Cash & Equivalents | $458K+746.0% | $54K+96.3% | $28K |
| Inventory | $81K-36.0% | $126K+169.2% | $47K |
| Accounts Receivable | $49K+425.3% | $9K-27.9% | $13K |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $5.1M+307.6% | $1.2M-55.7% | $2.8M |
| Current Liabilities | $2.7M+142.4% | $1.1M-56.1% | $2.6M |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | -$1.0M-128.1% | $3.7M+563.4% | $563K |
| Retained Earnings | -$986K-113.7% | -$461K+22.0% | -$592K |
NIVF Cash Flow Statement
| Metric | Q4'24 | Q4'23 | Q4'22 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
NIVF Financial Ratios
| Metric | Q4'24 | Q4'23 | Q4'22 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 1.17-1.0 | 2.19+1.3 | 0.94 |
| Debt-to-Equity | -4.82-5.2 | 0.33-4.6 | 4.98 |
| FCF Margin | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is NewGenIvf Group's annual revenue?
NewGenIvf Group (NIVF) reported $5.4M in total revenue for fiscal year 2024. This represents a 5.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewGenIvf Group's revenue growing?
NewGenIvf Group (NIVF) revenue grew by 5.8% year-over-year, from $5.1M to $5.4M in fiscal year 2024.
Is NewGenIvf Group profitable?
No, NewGenIvf Group (NIVF) reported a net income of -$525K in fiscal year 2024, with a net profit margin of -9.7%.
What is NewGenIvf Group's earnings per share (EPS)?
NewGenIvf Group (NIVF) reported diluted earnings per share of $-0.64 for fiscal year 2024. This represents a -118.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is NewGenIvf Group's EBITDA?
NewGenIvf Group (NIVF) had EBITDA of -$1.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is NewGenIvf Group's gross margin?
NewGenIvf Group (NIVF) had a gross margin of 33.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is NewGenIvf Group's operating margin?
NewGenIvf Group (NIVF) had an operating margin of -21.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is NewGenIvf Group's net profit margin?
NewGenIvf Group (NIVF) had a net profit margin of -9.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is NewGenIvf Group's free cash flow?
NewGenIvf Group (NIVF) generated -$8.3M in free cash flow during fiscal year 2024. This represents a -353.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewGenIvf Group's operating cash flow?
NewGenIvf Group (NIVF) generated -$8.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are NewGenIvf Group's total assets?
NewGenIvf Group (NIVF) had $3.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are NewGenIvf Group's capital expenditures?
NewGenIvf Group (NIVF) invested $53K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does NewGenIvf Group have outstanding?
NewGenIvf Group (NIVF) had 1M shares outstanding as of fiscal year 2024.
What is NewGenIvf Group's current ratio?
NewGenIvf Group (NIVF) had a current ratio of 1.17 as of fiscal year 2024, which is considered adequate.
What is NewGenIvf Group's debt-to-equity ratio?
NewGenIvf Group (NIVF) had a debt-to-equity ratio of -4.82 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NewGenIvf Group's return on assets (ROA)?
NewGenIvf Group (NIVF) had a return on assets of -14.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is NewGenIvf Group's cash runway?
Based on fiscal year 2024 data, NewGenIvf Group (NIVF) had $458K in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is NewGenIvf Group's debt-to-equity ratio negative or unusual?
NewGenIvf Group (NIVF) has negative shareholder equity of -$1.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is NewGenIvf Group's Piotroski F-Score?
NewGenIvf Group (NIVF) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewGenIvf Group's earnings high quality?
NewGenIvf Group (NIVF) has an earnings quality ratio of 15.75x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NewGenIvf Group cover its interest payments?
NewGenIvf Group (NIVF) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is NewGenIvf Group?
NewGenIvf Group (NIVF) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.